Total
0
Shares
EMVision (ASX:EMV) - Chairman, John Keep
Chairman, John Keep
Source: EMVision
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • EMVision Medical Devices (EMV) signs an $8 million project agreement with The Australian Stroke Alliance (ASA)
  • Under the project agreement, EMVision will receive $8 million in staged payments over a five-year period
  • This funding will support EMVision’s development and clinical validation of its first responder model for road and air ambulances
  • It is subject to project progression in a way that warrants continued funding at each stage and the ongoing achievement of project milestones
  • EMVision is up 4.26 per cent on the market with shares trading at $2.94 at 11:53 am AEST

EMVision Medical Devices (EMV) has signed an $8 million project agreement with The Australian Stroke Alliance (ASA).

Under the project agreement, EMVision will receive $8 million in cash funding in staged payments over a five-year period.

This funding will support EMVision’s development and clinical validation of its first responder model for road and air ambulances.

The funding is subject to project progression in a way that warrants continued funding at each stage and the ongoing achievement of project milestones.

EMVision will retain sole intellectual property (IP) and has agreed to pay the ASA a two per cent royalty of net sales.

The ASA may terminate the project agreement with 30 days written notice if EMVision is unable to meet a milestone and is unable to resolve it within a reasonable timeframe.

CEO Ron Weinberger commented on the agreement.

“We have been working closely with our colleagues at the Australian Stroke Alliance for number of years now,” Dr Weinberger said. “The support from the ASA in this time has been outstanding

“The support from the ASA in this time has been outstanding. We are pleased to advance our partnership with the signing of our project agreement and unlock our non-dilutive medical research future fund (MRFF) grant funding.”

EMVision was up 4.26 per cent on the market with shares trading at $2.94 at 11:53 am AEST.

EMV by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.